Items Tagged ‘Leukemia’

September 19th, 2017

Pass it On: It’s Leukemia National Awareness Month

By

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates that 81,080 new cases and 21,270 deaths will occur in the United States in […]

View full entry

Tags: all, AML, CLL, CML, Leukemia, News


September 5th, 2017

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, AML, CD33 antigen, gemtuzumab ozogamicin, Leukemia, Mylotarg, News, Precision Cancer Medicine, targeted therapy


September 1st, 2017

FDA Approves First Gene Therapy

By

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cell-based gene therapy, Kymriah, Leukemia, News, tisagenlecleucel


September 1st, 2017

FDA Approves First Gene Therapy

By

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cell-based gene therapy, Kymriah, Leukemia, News, tisagenlecleucel


August 22nd, 2017

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia

By

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children under 15 years old and is the most common childhood cancer in the US1. Effective treatment options for patients with r/r […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, B-cell, Besponsa, Inotuzumab, Leukemia, News, ozogamicin, targeted therapy


August 10th, 2017

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the Real Time IDH2 Assay, which is used to detect specific mutations in the IDH2 […]

View full entry

Tags: Acute Myeloid Leukemia, AML, Enasidenib, Idhifa, Leukemia, News


July 12th, 2017

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

By

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available  Positive ODAC recommendation is latest milestone for CTL019 program that started through collaboration […]

View full entry

Tags: car-t immunotherapy, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma


June 20th, 2017

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia

By

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, AML, asco, blood cancer, COMFORT 1, Enasidenib, IDH2 gene, jakafi, Leukemia, myelofibrosis, News


June 14th, 2017

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia

By

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients with the condition and, in many ways, ushered in the era of molecularly-targeted treatments against cancer. […]

View full entry

Tags: BCR-ABL, Chronic Myeloid Leukemia, CML, dasatinib), Gleevec, imatinib, Leukemia, News, Philadelphia chromosome Sprycel


June 5th, 2017

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients

By

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center (ACC). The team will present the results from its pilot study […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CTL119, ibrutinib, kinase inhibitor, Leukemia, News, Personalized Cell Therapy, personalized cellular therapy


May 2nd, 2017

Have a Question about Chronic Myeloid Leukemia? Join us on May 25th!

By

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017, Dr. Luskin will answer your pre-submitted questions about chronic myeloid leukemia (CML) on CancerConnect. CancerConnect is an online support community for individuals affected by cancer. Dr. Luskin […]

View full entry

Tags: Chronic Myeloid Leukemia, cml expert, expert, Leukemia, News


December 14th, 2016

FDA Grants Iclusig® Expanded Approval for CML

By

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, CML, Iclusig, Leukemia, News, PACE trial, Ph+ ALL, ponatinib, TKI, tyrosine kinase inhibitor


December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

By

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or […]

View full entry

Tags: Blood transfusions, Hodgkin's Lymphoma, Leukemia, long-term, Multiple Myeloma, Myeloproliferative Neoplasms MPN, News, Non-Hodgkin's Lymphoma, short-term, storage


November 17th, 2016

FDA Priority Review Granted for Midostaurin in Leukemia

By

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The diagnostic test to detect the FLT3 mutation has also been accepted for review by […]

View full entry

Tags: Acute Myeloid Leukemia, AML, fda, FLT3 mutation, itchy skin, Leukemia, mast cell, mastocytosis, midostaurin, News, PKC412


September 26th, 2016

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia

By

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab) to standard chemotherapy. ALL in children is a malignant disease, or cancer of the blood, characterized by the rapid uncontrolled growth of abnormal, […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, CD20-positive, Childhood Acute Lymphoblastic Leukemia, children, Leukemia, News, Ph-negative, Philadelphia chromosome (PH)-negative acute lymphoblastic leukemia